N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Personalized Addiction Treatment enHancement

Sponsor: Rhode Island Hospital • ClinicalTrials.gov ID: NCT07778394

Registry updated: 2026-08-26
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Many patients stop medication-based treatments for Opioid Use Disorder (OUD) prematurely, placing them at increased risk for overdose and death. Providing targeted interventions for OUD, particularly through an accessible, digital health platform, is a potential way to enhance recovery and keep patients engaged in care. The current study seeks to test whether a digital mental health platform, delivered by peer recovery support specialists to individuals prescribed buprenorphine or methadone medication, will improve treatment outcomes for this high risk population.

Interventions

  • Vira Platform (Behavioral)
    The Vira Platform is a digitally enhanced mental health care platform consisting of a patient smartphone application that utilizes mobile sensing to garner insight about patterns of behavior related to negative affect, sleep, and anhedonia while simultaneously providing just-in-time nudges to increase positive interactions with the environment. Behavioral activation is the primary intervention being deployed through the Vira App. It is accompanied by a practitioner platform that is delivered through certified peer recovery support specialist to encourage engagement with the app and promote social support.
  • Treatment-As-Usual (Behavioral)
    The treatment-as-usual condition consists of standard outpatient buprenorphine or methadone treatment. These medications are among those considered to be the gold standard of care for treating opioid use disorder, and therefore, represents an adequate control intervention for this study.

Eligibility criteria

Inclusion Criteria: * Age 22+ * Current Opioid Use Disorder diagnosis * Prescribed buprenorphine or methadone * Initiated or reinitiated buprenorphine or methadone treatment recently * Access to personal smartphone Exclusion Criteria: * Not fluent in English * Limited mental capacity or inability to provided informed consent

Conditions

Opioid Use Disorder mHealth Peer Support

Locations

  • Rhode Island Hospital — Providence, Rhode Island, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record